Sandoz, a division of Novartis, is a global leader in biosimilar and generic medicines.  At Sandoz, we pioneer novel approaches to help people around the world access high-quality medicine across a number of therapeutic areas, including Rheumatology.  We provide affordable medication to contribute to the sustainability of healthcare systems worldwide.

Sandoz has recently launched Hyrimoz® (adalimumab) which is listed on the PBS for matching indications to reference adalimumab (Humira), except where a dose <40mg is required*1

If you would like to receive more information about Hyrimoz or the support services available from Sandoz, connect with one of our team members.

PBS Information: Authority required for initial and first continuing treatment courses. Authority required (STREAMLINED) for subsequent continuing courses. Refer to PBS schedule for full authority information.

Please review Product Information before prescribing. The product information can be accessed HERE
*Hyrimoz is not PBS listed for the treatment of patients with severe juvenile idiopathic arthritis weighing less than 30 kg.

Reference: 1. Pharmaceutical Benefits Scheme. Adalimumab. Accessed on April 28, 2021. Accessed from: https://www.pbs.gov.au/pbs/search?term=adalimumab

Sandoz Pty Ltd | ABN 60 075 449 553 | 54 Waterloo Road Macquarie Park, NSW 2113 Australia | Tel:1800 726 369  | Hyrimoz® is a registered trademark of Novartis AG | MLRID 140598 | JULY 2021